REG - Genedrive PLC - Commence of roll out in Greater Manchester

GenedriveAnnouncement

20/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230320:nRST4435Ta&default-theme=true

RNS Number : 4435T  Genedrive PLC  20 March 2023

genedrive plc

("genedrive" or the "Company")

 

Genedrive® MT-RNR1 to commence roll out in Greater Manchester

Project to follow NICE final recomendations scheduled for end of this month

 

genedrive plc (AIM:GDR), the point of care molecular diagnostics company,
announces that the Genedrive® MT-RNR1 ID Kit is in process for roll out at
two further hospital sites in the North West NHS. The implementation project,
scheduled to commence from April,  will follow the NICE final recommendation
for the use of the Genedrive MT-RNR1 ID test in the NHS (England and Wales)
which is due towards the end of this month.

 

The Manchester Academic Health Science Centre (MAHSC) Women and Children
Domain, part of Health Innovation Manchester (HInM) are supporting and project
managing the further roll out across Manchester University NHS Foundation
Trust.  The Company continues to work alongside HInM on specific plans for
the roll out across an additional  five neonatal sites in Greater Manchester.
Once fully subscribed at this regional level, the test would be available when
needed to circa 30000 newborns over the next NHS fiscal year, of which 10-12%
are modelled to be admitted to a regional neonatal unit.

 

MAHSC is one of eight national centres designated by NHS England and the
National Institute for Health and Care Research for demonstrating excellence
in patient care and driving innovation into the health service.

 

Dr. Ajit Mahaveer, Clinical Head of Division - Newborn Services, Manchester
University NHS Foundation Trust (MFT) said: "The Genedrive MT-RNR1 test was
piloted here at MFT. This initiative will allow us to expand testing to the
neonatal units at North Manchester General Hospital and Wythenshawe Hospital.
We are also intending to work with NICE on ongoing data collection to support
the long term recommendations for the product."

 

Jonathan Massey, Programme Director for Academia at Health Innovation
Manchester said: "The Genedrive MT-RNR1 test was developed alongside our NHS
partners and supported by the National Institute for Health and Care
Research.  This programme will support its wider adoption across the
city-region, ensuring that the work done to date will translate to better and
equitable patient outcomes, wherever a child is treated in Greater
Manchester."

 

David Budd, CEO of genedrive plc, said: "While we work with clinicians and
implementers nationally on a Trust by Trust basis, near-term roll outs such as
this one in Greater Manchester will benefit from additional coordination and
support.  We are grateful for the engagement from HInM and MFT, which will be
an example for future regional roll outs elsewhere in the country. It's an
important milestone for the Company as we work to ensuring every newborn has
access to the Genedrive MT-RNR1 ID test when needed."

 

The Genedrive® MT-RNR1 ID Kit is the world's first commercial point-of-care
genetic test for emergency care. It helps to avoid irreversible lifelong
hearing loss in specific infants exposed to aminoglycosides by rapidly
detecting the m.1555A>G gene variant that can cause deafness, allowing for
alternative antibiotics to be prescribed. Product information can be found at
https://www.genedrive.com/assays/rnr1-product.php
(https://www.genedrive.com/assays/rnr1-product.php)

 

For further details please contact:

 

 genedrive plc                                       +44 (0)161 989 0245
 David Budd: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Joint Broker)  +44 (0)20 7418 8900
 James Steel / Oliver Duckworth

 finnCap (Joint Broker)                              +44 (0)20 7220 0500
 Geoff Nash / Alice Lane

 Walbrook PR Ltd (Media & Investor Relations)        +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                     (mailto:genedrive@walbrookpr.com)
 Paul McManus / Anna Dunphy                          +44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com/) )  genedrive plc is a molecular diagnostics
company developing and commercialising a low cost, rapid, versatile, simple to
use and robust point of need molecular diagnostics platform for the diagnosis
of infectious diseases and for use in patient stratification (genotyping),
pathogen detection and other indications. The Company has assays on the market
for the detection of MT-RNR1, HCV, certain military biological targets, a high
throughput SARS-CoV-2 assay and a point of care test for Covid-19. The company
are currently developing a genetic test for CYP2C19 metaboliser status.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBCGDXIDBDGXC